TABLE 1 Clinical studies assessing the efficacy/safety of a linezolid daily dosage of 300 mg in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients
First author [ref.]Patients nDrug resistanceStudy designMain results
Koh [7]24MDR/XDR-TBRetrospectiveSputum conversion in 92%
Alffenaar [8]8MDR/XDR-TBOpen-label, prospective, pharmacokineticEffective serum concentrations after 3 days of administration
Koh [9]51MDR/XDR-TBRetrospectiveTreatment success in 78%, neurotoxicity in 27%
Lee [3]16XDR-TBClinical trialAdverse events in 69%